TSHA · Insider Trading
Taysha Gene Therapies, Inc. Common Stock
Every open-market purchase and sale reported by TSHA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Sukumar Nagendran | President and Head of R&D | Sell | −200,000 | −$1.25M |
| 2026-06-02 | Laura Sepp-Lorenzino | Director | A | +21,335 | — |
| 2026-06-02 | Alison S Long | Director | A | +21,335 | — |
| 2026-06-02 | John A Stalfort III | Director | A | +21,335 | — |
| 2026-06-02 | Phillip B. Donenberg | Director | A | +21,335 | — |
| 2026-04-13 | Sukumar Nagendran | President and Head of R&D | MIXED | −180,979 | −$859.47K |
| 2026-02-06 | Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | −1,655 | −$7.48K |
| 2026-01-27 | Sukumar Nagendran | President and Head of R&D | Sell | −116,050 | −$547.47K |
| 2026-01-27 | Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | −102,817 | −$485.04K |
| 2026-01-27 | Sean P. Nolan | Chief Executive Officer | Sell | −178,101 | −$840.20K |
| 2026-01-14 | Kamran Alam | CHIEF FINANCIAL OFFICER | A | +359,000 | — |
| 2026-01-14 | Sean P. Nolan | Chief Executive Officer | A | +1,008,000 | — |
| 2026-01-14 | Sukumar Nagendran | President and Head of R&D | MIXED | +427,000 | −$712.56K |
| 2025-12-01 | Sukumar Nagendran | President and Head of R&D | MIXED | — | −$1.13M |
| 2025-09-12 | Sukumar Nagendran | President and Head of R&D | MIXED | −158,850 | −$617.24K |
| 2025-08-22 | Sukumar Nagendran | President and Head of R&D | Sell | −57,054 | −$162.60K |
| 2025-08-22 | Kamran Alam | CHIEF FINANCIAL OFFICER | Sell | −54,491 | −$155.30K |
| 2025-06-04 | John A Stalfort III | Director | A | +56,623 | — |
| 2025-06-04 | Alison S Long | Director | A | +56,623 | — |
| 2025-06-04 | Phillip B. Donenberg | Director | A | +56,623 | — |
| 2025-06-04 | Laura Sepp-Lorenzino | Director | A | +56,623 | — |
| 2025-06-03 | Paul B Manning | 10%+ Owner | Buy | +750,000 | +$2.06M |
| 2025-04-10 | Kamran Alam | CHIEF FINANCIAL OFFICER | A | +12,462 deriv. | — |
| 2025-03-13 | Kamran Alam | CHIEF FINANCIAL OFFICER | F | −29,843 | −$50.43K |
| 2025-01-03 | Kamran Alam | CHIEF FINANCIAL OFFICER | A | +431,000 | — |
| 2025-01-03 | Sean P. Nolan | Chief Executive Officer | A | +892,500 | — |
| 2025-01-03 | Sukumar Nagendran | President and Head of R&D | A | +324,500 | — |
| 2024-07-01 | Paul B Manning | 10%+ Owner | Buy | +1,333,333 | +$3.00M |
| 2024-05-31 | Alison S Long | Director | A | +49,220 | — |
| 2024-05-31 | Laura Sepp-Lorenzino | Director | A | +49,220 | — |
| 2024-05-31 | Phillip B. Donenberg | Director | A | +49,220 | — |
| 2024-05-31 | John A Stalfort III | Director | A | +49,220 | — |
| 2024-02-06 | Kamran Alam | CHIEF FINANCIAL OFFICER | F | −1,288 | −$1.94K |
| 2024-01-04 | Kamran Alam | Chief Financial Officer | A | +590,413 | — |
| 2024-01-04 | Sean P. Nolan | Chief Executive Officer | A | +1,184,688 | — |
| 2024-01-04 | Sukumar Nagendran | President and Head of R&D | A | +863,617 | — |
| 2023-12-18 | Sean P. Nolan | Chief Executive Officer | A | +466,550 deriv. | — |
| 2023-12-18 | Kamran Alam | Chief Financial Officer | A | +187,582 deriv. | — |
| 2023-12-18 | Sukumar Nagendran | President and Head of R&D | A | +334,005 deriv. | — |
| 2023-11-20 | Paul B Manning | 10%+ Owner | Buy | +100,000 | +$163.00K |
| 2023-11-03 | Alison S Long | Director | A | +43,800 deriv. | — |
| 2023-08-25 | Kamran Alam | Chief Financial Officer | Sell | −33,000 | −$76.89K |
| 2023-08-16 | Phillip B. Donenberg | Director | Buy | +111,111 | +$100.00K |
| 2023-08-16 | Paul B Manning | 10%+ Owner | Buy | +16,466,667 | +$14.82M |
| 2023-08-16 | John A Stalfort III | Director | MIXED | +827,778 | +$700.00K |
| 2023-08-16 | Sean P. Nolan | Chief Executive Officer | Buy | +444,444 | +$400.00K |
| 2023-07-14 | R.A. Session II | 10%+ Owner | Sell | −85,872 | −$60.77K |
| 2023-06-26 | John A Stalfort III | Director | A | +43,800 deriv. | — |
| 2023-06-26 | Phillip B. Donenberg | Director | A | +36,200 deriv. | — |
| 2023-06-26 | Laura Sepp-Lorenzino | Director | A | +36,200 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sean P. Nolan | Chief Executive Officer | 4,443,802 | $17.82M |
| John A Stalfort III | Director | 2,060,849 | $8.26M |
| Kamran Alam | CHIEF FINANCIAL OFFICER | 1,442,131 | $5.78M |
| Paul B Manning | Director | 1,355,333 | $5.43M |
| Sukumar Nagendran | President and Head of R&D | 936,410 | $3.76M |
| Phillip B. Donenberg | Director | 241,289 | $967.57K |
| Laura Sepp-Lorenzino | Director | 127,178 | $509.98K |
| Alison S Long | Director | 127,178 | $509.98K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TSHA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.